Overview
SLU-PP-332 is a synthetic small-molecule pan-agonist of all three Estrogen-Related Receptors (ERRα, ERRβ, and ERRγ) — orphan nuclear receptors that function as master regulators of mitochondrial biogenesis, fatty acid oxidation, and oxidative metabolism. Developed at St. Louis University (hence 'SLU'), SLU-PP-332 was the first compound to demonstrate that pharmacological ERR pan-activation can replicate the transcriptional signature of acute aerobic exercise in skeletal muscle, earning it the designation of 'exercise mimetic.' In mouse models, it increased exercise endurance, enhanced fatty acid oxidation, promoted type IIa oxidative muscle fiber formation, and alleviated metabolic syndrome markers — all without physical training.
Mechanism of Action
SLU-PP-332 acts as a pan-agonist at all three Estrogen-Related Receptors (ERRα, ERRβ, ERRγ) — orphan nuclear receptors that are constitutively active and do not require endogenous ligands for baseline activity. Upon SLU-PP-332 binding, ERR activity is amplified, driving the transcription of target genes involved in mitochondrial biogenesis, fatty acid β-oxidation, and oxidative phosphorylation. The primary downstream effector is PGC-1α (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha) — the master regulator of mitochondrial biogenesis. ERRα directly binds to ERR Response Elements (ERREs) in the promoters of PGC-1α target genes, creating a positive feedback loop: PGC-1α c
Research Evidence
- SLU-PP-332 enhanced exercise endurance in mice by ~50% after 14 days of treatment (50 mg/kg b.i.d., i.p.), an effect completely abolished in skeletal muscle-specific ERRα knockout mice, confirming ERRα as the primary mediator (Billon et al., 2023, PMC11584170)
- In mouse models of obesity and metabolic syndrome, SLU-PP-332 administration increased energy expenditure, enhanced fatty acid oxidation, reduced adiposity, and improved insulin sensitivity — replicating the metabolic benefits of endurance exercise without physical training (Sitaula et al., 2024, PMID 38320755)
- SLU-PP-332 induced a transcriptional signature in skeletal muscle that closely matched the acute aerobic exercise genetic program, including upregulation of DDIT4, SLC25A25, PER1, ALAS2, and multiple electron transport chain components
- The compound increased type IIa oxidative skeletal muscle fiber content and enhanced mitochondrial respiration in C2C12 myocytes, demonstrating direct effects on muscle fiber phenotype and mitochondrial function
- Novel ERR pan-agonists derived from SLU-PP-332's scaffold demonstrated cardioprotective effects in heart failure models by boosting cardiac fatty acid metabolism and mitochondrial function (Hegazy et al., 2022, bioRxiv)
Bottom line: SLU-PP-332 is a genuinely novel compound with a clearly defined mechanism, validated in genetic knockout models, and published in peer-reviewed journals. It is not a peptide — it is a small molecule that acts on nuclear receptors. All published data is preclinical (mice). No human data exists. The exercise-mimetic concept is scientifically compelling but requires human trials before any therapeuti
Research Protocols & Dosage
Evidence-based research protocols, administration routes, and dosage considerations for SLU-PP-332 are detailed in the full compound profile. See also: Dosage guide for SLU-PP-332.
Sourcing & Quality
SLU-PP-332 is available from Purgo Labs with third-party COA verification and research-grade purity standards. View SLU-PP-332 at Purgo Labs.